Related Experiment Videos
Troponin in acute coronary syndrome patients. The interventional cardiologist perspective
E Stabile1, T Kinnaird, S Fuchs
1Cardiovascular Research Institute, Cardiac Catheterization Laboratories, Washington Hospital Center, Washington, DC 20010, USA.
Insights
Troponin measurements are crucial for diagnosing acute coronary syndromes (ACS) and identifying high-risk patients. This review explores using troponin levels to guide treatment strategies for non-ST elevation ACS.
Area of Science:
- Cardiology
- Biomarkers
- Clinical Diagnostics
Background:
- Troponin measurement is integral to assessing acute coronary syndromes (ACS).
- Troponin offers superior sensitivity and specificity over creatine kinase MB fraction for identifying high-risk ACS patients.
- Aggressive treatment, including antiplatelet therapy and percutaneous intervention, can modify the prognosis of high-risk ACS patients.
Purpose of the Study:
- To review troponin measurement as a clinical tool for tailoring therapeutic strategies in non-ST elevation ACS.
- To discuss the predictive value of postintervention troponin levels.
Main Methods:
- Review of available clinical data on troponin measurement in non-ST elevation ACS.
- Analysis of studies evaluating troponin levels for treatment guidance.
- Examination of data on postintervention troponin levels.
Main Results:
- Troponin measurement effectively identifies high-risk ACS patients.
- Troponin levels can guide more aggressive treatment strategies for non-ST elevation ACS.
- Postintervention troponin levels may have predictive value.
Conclusions:
- Troponin measurement is a vital tool for risk stratification and treatment individualization in non-ST elevation ACS.
- Further investigation into postintervention troponin levels is warranted.
Abstract:
Troponin measurement has now become an integral part of the assessment of patients with acute coronary syndromes (ACS). Obtaining troponin levels have been used effectively as a diagnostic tool with superior sensitivity and specificity compared to creatine kinase MB fraction in identifying high-risk ACS patients. The adverse prognosis of these high-risk patients can be modified by more aggressive treatment strategy including antiplatelet and antithrombotic therapy accompanied, if feasible, by early percutaneous intervention. The current review summarizes available data on troponin measurement as a clinical tool for tailoring therapeutic strategy in non-ST elevation ACS patients. In addition, the data on the potential predictive value of postintervention troponin levels is discussed.